Literature DB >> 16260906

AIDS events among individuals initiating HAART: do some patients experience a greater benefit from HAART than others?

C Sabine1.   

Abstract

OBJECTIVE: To describe the rate of new AIDS events over the first year of HAART in patients with different characteristics and to describe the decrease in incidence of AIDS between the first and second 6 months of the year in these patients.
DESIGN: Collaboration of cohort studies from Europe and North America.
METHODS: AIDS rates in the first year of HAART were calculated for 22 217 antiretroviral-naive individuals. Event rates were compared in the periods 0-6 and 7-12 months after starting HAART.
RESULTS: The number of events and person-years of follow-up (PYFU) in the two time periods were 1185 (9601) and 336 (8690), respectively (event rates: 12.3 and 3.9 per 100 PYFU, relative decline in incidence: 68%). Whereas rates decreased in all groups, tests for interaction suggested that relative declines in incidence were more rapid in homosexual men (P = 0.002), in those starting HAART from 2001 in comparison with earlier years (P = 0.03), in those with lower CD4 cell counts (P-values of 0.001, 0.002 and 0.11 for those with cell counts < 50, 50-199 and 200-349 cells/microl compared to those with cell counts >or= 350 cells/microl) and HIV RNA levels >or= 5 log10 copies/ml (P = 0.0008). Those with AIDS at the time of starting HAART had a less rapid relative decline in incidence (P = 0.0007).
CONCLUSIONS: Our results suggest that some groups may experience less rapid relative declines in AIDS incidence than others over the first year on HAART.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16260906     DOI: 10.1097/01.aids.0000189858.59559.d2

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  6 in total

Review 1.  When to start antiretroviral therapy.

Authors:  Cunlin Wang; Saba W Masho; Daniel E Nixon
Journal:  Curr HIV/AIDS Rep       Date:  2006-07       Impact factor: 5.071

2.  Analysis of randomized comparative clinical trial data for personalized treatment selections.

Authors:  Tianxi Cai; Lu Tian; Peggy H Wong; L J Wei
Journal:  Biostatistics       Date:  2010-09-28       Impact factor: 5.899

Review 3.  Sex differences in HIV outcomes in the highly active antiretroviral therapy era: a systematic review.

Authors:  Jessica L Castilho; Vlada V Melekhin; Timothy R Sterling
Journal:  AIDS Res Hum Retroviruses       Date:  2014-02-07       Impact factor: 2.205

4.  Cohort profile: Antiretroviral Therapy Cohort Collaboration (ART-CC).

Authors:  Margaret T May; Suzanne M Ingle; Dominique Costagliola; Amy C Justice; Frank de Wolf; Matthias Cavassini; Antonella D'Arminio Monforte; Jordi Casabona; Robert S Hogg; Amanda Mocroft; Fiona C Lampe; François Dabis; Gerd Fätkenheuer; Timothy R Sterling; Julia del Amo; M John Gill; Heidi M Crane; Michael S Saag; Jodie Guest; Hans-Reinhard Brodt; Jonathan A C Sterne
Journal:  Int J Epidemiol       Date:  2013-04-18       Impact factor: 7.196

5.  The independent effect of highly active antiretroviral therapy on severe opportunistic disease incidence and mortality in HIV-infected adults in Côte d'Ivoire.

Authors:  Elena Losina; Yazdan Yazdanpanah; Sylvie Deuffic-Burban; Bingxia Wang; Lindsey L Wolf; Eugène Messou; Delphine Gabillard; Catherine Seyler; Kenneth A Freedberg; Xavier Anglaret
Journal:  Antivir Ther       Date:  2007

6.  Clinical progression rates by CD4 cell category before and after the initiation of combination antiretroviral therapy (cART).

Authors:  Marguerite Guiguet; Kholoud Porter; Andrew Phillips; Dominique Costagliola; Abdel Babiker
Journal:  Open AIDS J       Date:  2008-02-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.